Clinical Trials Logo

Advanced Cancer clinical trials

View clinical trials related to Advanced Cancer.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 7

NCT ID: NCT00761618 Active, not recruiting - Advanced Cancer Clinical Trials

Intrapleural Catheter Daily Versus Three Times a Week Drainage

Start date: August 22, 2008
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if draining the IPC every day is better at than draining it 3 times a week.

NCT ID: NCT00591422 Active, not recruiting - Advanced Cancer Clinical Trials

Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas

Start date: August 2007
Phase: Phase 1
Study type: Interventional

The study of Dariniparsin (ZIO-101-C) in Advanced Solid Tumors and Non-Hodgkin's Lymphomas

NCT ID: NCT00488072 Active, not recruiting - Insomnia Clinical Trials

Effects of Mirtazapine on Appetite in Advanced Cancer Patients

Start date: September 20, 2006
Phase: Phase 2
Study type: Interventional

Primary objective: This is a preliminary study to determine if Mirtazapine in comparison to placebo will improve appetite in advanced cancer patients with anorexia and weight loss. An improvement of appetite is defined as a decrease of 2 in the appetite score from baseline on the Edmonton Symptom Assessment Scale (ESAS) at day 15 (+/-3 days). Secondary objective-A: To determine if Mirtazapine in comparison to placebo will improve insomnia ( as measured by Pittsburgh Sleep Quality Index) on day 15 ( +/- 3 days), and day 29 ( +/- 3 days) Secondary objective - B: To determine if Mirtazapine in comparison to placebo will improve other common symptoms such as pain, nausea and fatigue( as measured by ESAS), depression and anxiety ( as measured by Hospital Anxiety and Depression scale), and quality of life ( as measured by Functional Assessment of Anorexia/Cachexia Therapy ) in advanced cancer patients with anorexia/cachexia, on days 15 (+/-3 days), and 29 (+/-3 days) Other Objectives: To provide exploratory data on the effects of Mirtazapine on weight gain, and preservation/gain lean muscle mass ( anthropometric measurements and Bioelectric Impedance), on days 15 (+/-3 days), and 29 (+/-3 days). To provide exploratory data on the effects of a Mirtazapine dose increase to 30 mg on decreased side effects of drug and increased appetite on day 29 (+/-3 days).

NCT ID: NCT00214838 Active, not recruiting - Advanced Cancer Clinical Trials

An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer

Start date: March 2005
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objectives of this study are to identify the maximum tolerated dose and to evaluate safety of atiprimod in patients with advanced cancer.